Perianal Fistulizing Crohn’s Disease–Associated Anorectal and Fistula Cancers: Systematic Review and Expert Consensus

• Published in: Clinical gastroenterology and hepatology
• Main Authors: Wong, Serre-Yu, Rowan, Cathy, Brockmans, Elvira Diaz, Law, Cindy C.Y., Giselbrecht, Elisabeth, Ang, Celina, Khaitov, Sergey, Sachar, David, Polydorides, Alexandros D., Winata, Leon Shin-han, Verstockt, Bram, Spinelli, Antonino, Rubin, David T., Deepak, Parakkal, McGovern, Dermot P.B., McDonald, Benjamin D., Lung, Phillip, Lundby, Lilli, Lightner, Amy L., Holubar, Stefan D., Hanna, Luke, Hamarth, Carla, Geldof, Jeroen, Dige, Anders, Cohen, Benjamin L., Carvello, Michele, Bonifacio, Cristiana, Bislenghi, Gabriele, Behrenbruch, Corina, Ballard, David H., Altinmakas, Emre, Sebastian, Shaji, Tozer, Phil, Hart, Ailsa, Colombel, Jean-Frederic
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 12.06.2024
• Subjects: Anorectal Cancer; Inflammatory Bowel Disease; Perianal Fistulizing Crohn’s Disease; CD; AAC; CRT; MRI; SCCA; IBD; HPV; EUA; CT; PFCD; MA; CRC; Perianal Fistulizing Crohn’s Disease; Anorectal Cancer; Inflammatory Bowel Disease; PET
• ISSN: 1542-3565; 1542-7714; 1542-7714
• DOI: 10.1016/j.cgh.2024.05.029

Perianal fistulizing Crohn’s disease (PFCD)-associated anorectal and fistula cancers are rare but often devastating diagnoses. However, given the low incidence and consequent lack of data and clinical trials in the field, there is little to no guidance on screening and management of these cancers. To inform clinical practice, we developed consensus guidelines on PFCD-associated anorectal and fistula cancers by multidisciplinary experts from the international TOpClass consortium. We conducted a systematic review by standard methodology, using the Newcastle-Ottawa Scale quality assessment tool. We subsequently developed consensus statements using a Delphi consensus approach. Of 561 articles identified, 110 were eligible, and 76 articles were included. The overall quality of evidence was low. The TOpClass consortium reached consensus on 6 structured statements addressing screening, risk assessment, and management of PFCD-associated anorectal and fistula cancers. Patients with long-standing (>10 years) PFCD should be considered at small but increased risk of developing perianal cancer, including squamous cell carcinoma of the anus and anorectal carcinoma. Risk factors for squamous cell carcinoma of the anus, notably human papilloma virus, should be considered. New, refractory, or progressive perianal symptoms should prompt evaluation for fistula cancer. There was no consensus on timing or frequency of screening in patients with asymptomatic perianal fistula. Multiple modalities may be required for diagnosis, including an examination under anesthesia with biopsy. Multidisciplinary team efforts were deemed central to the management of fistula cancers. Inflammatory bowel disease clinicians should be aware of the risk of PFCD-associated anorectal and fistula cancers in all patients with PFCD. The TOpClass consortium consensus statements outlined herein offer guidance in managing this challenging scenario.